Cellular HIV-1 DNA levels in patients receiving antiretroviral therapy strongly correlate with therapy initiation timing but not with therapy duration

BMC Infectious Diseases

Volumn 11, Issue , 2011, Pages

  Watanabe, Dai ^a   Ibe, Shiro ^b   Uehira, Tomoko ^a   Minami, Rumi ^c   Sasakawa, Atsushi ^a   Yajima, Keishiro ^a   Yonemoto, Hitoshi ^a   Bando, Hiroki ^a   Ogawa, Yoshihiko ^a   Taniguchi, Tomohiro ^a   Kasai, Daisuke ^a   Nishida, Yasuharu ^a   Yamamoto, Masahiro ^c   Kaneda, Tsuguhiro ^d   Shirasaka, Takuma ^a  

^a OSAKA NATIONAL HOSPITAL   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^d KINJO GAKUIN UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CELL DNA; VIRUS DNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHRONIC DISEASE; DNA DETERMINATION; DNA PURIFICATION; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PERIPHERAL LYMPHOCYTE; SEROCONVERSION; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS DETECTION; VIRUS LOAD; CD4+ T LYMPHOCYTE; CELL CULTURE; CROSS-SECTIONAL STUDY; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; ISOLATION AND PURIFICATION; MIDDLE AGED; PHYSIOLOGY; TIME; VIROLOGY;

ADULT; ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; RNA, VIRAL; TIME FACTORS; VIRAL LOAD;

EID: 79956267508     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-11-146     Document Type: Article

References (36)

1. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD, Siliciano RF. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278(5341):1295-1300. 10.1126/science.278.5341.1295, 9360927.
2. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, Kovacs C, Gange SJ, Siliciano RF. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003, 9(6):727-728. 10.1038/nm880, 12754504.
3. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, Hermankova M, Chadwick K, Margolick J, Quinn TC, Kuo YH, Brookmeyer R, Zeiger MA, Barditch-Crovo P, Siliciano RF. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997, 387(6629):183-188. 10.1038/387183a0, 9144289.
4. Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2009, Department of Health and Human Services, Panel on Antiretroviral Guidelines for Adults and Adolescents.
5. Koelsch KK, Liu L, Haubrich R, May S, Havlir D, Gunthard HF, Ignacio CC, Campos-Soto P, Little SJ, Shafer R, Robbins GK, D'Aquila RT, Kawano Y, Young K, Dao P, Spina CA, Richman DD, Wong JK. Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. J Infect Dis 2008, 197(3):411-419. 10.1086/525283, 18248304.
6. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, Boucher G, Boulassel MR, Ghattas G, Brenchley JM, Schacker TW, Hill BJ, Douek DC, Routy JP, Haddad EK, Sekaly RP. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009, 15(8):893-900. 10.1038/nm.1972, 2859814, 19543283.
7. Wada K, Nagai H, Hagiwara T, Ibe S, Utsumi M, Kaneda T. Delayed HIV-1 infection of CD4+ T lymphocytes from therapy-naive patients demonstrated by quantification of HIV-1 DNA copy numbers. Microbiol Immunol 2004, 48(10):767-772.
8. Nagai H, Wada K, Morishita T, Utsumi M, Nishiyama Y, Kaneda T. New estimation method for highly sensitive quantitation of human immunodeficiency virus type 1 DNA and its application. J Virol Methods 2005, 124(1-2):157-165. 10.1016/j.jviromet.2004.11.025, 15664064.
9. Kondo M, Sudo K, Tanaka R, Sano T, Sagara H, Iwamuro S, Takebe Y, Imai M, Kato S. Quantitation of HIV-1 group M proviral DNA using TaqMan MGB real-time PCR. J Virol Methods 2009, 157(2):141-146. 10.1016/j.jviromet.2008.12.006, 19126416.
10. Kabamba-Mukadi B, Henrivaux P, Ruelle J, Delferriere N, Bodeus M, Goubau P. Human immunodeficiency virus type 1 (HIV-1) proviral DNA load in purified CD4+ cells by LightCycler real-time PCR. BMC Infect Dis 2005, 5(1):15. 10.1186/1471-2334-5-15, 1274269, 15780144.
11. Redel L, Le Douce V, Cherrier T, Marban C, Janossy A, Aunis D, Van Lint C, Rohr O, Schwartz C. HIV-1 regulation of latency in the monocyte-macrophage lineage and in CD4+ T lymphocytes. J Leukoc Biol 2010, 87(4):575-588. 10.1189/jlb.0409264, 19801499.
12. Valcour VG, Shiramizu BT, Shikuma CM. HIV DNA in circulating monocytes as a mechanism to dementia and other HIV complications. J Leukoc Biol 2010, 87(4):621-626. 10.1189/jlb.0809571, 2858306, 20130221.
13. Rozera G, Abbate I, Bruselles A, Vlassi C, D'Offizi G, Narciso P, Chillemi G, Prosperi M, Ippolito G, Capobianchi MR. Massively parallel pyrosequencing highlights minority variants in the HIV-1 env quasispecies deriving from lymphomonocyte sub-populations. Retrovirology 2009, 6:15. 10.1186/1742-4690-6-15, 2660291, 19216757.
14. Marchetti G, Gori A, Casabianca A, Magnani M, Franzetti F, Clerici M, Perno CF, Monforte A, Galli M, Meroni L. Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART. AIDS 2006, 20(13):1727-1736. 10.1097/01.aids.0000242819.72839.db, 16931937.
15. Sarmati L, Parisi SG, Nicastri E, d'Ettorre G, Palmisano L, Andreotti M, Andreoni C, Giuliano M, Gatti F, Boldrin C, Palu G, Vullo V, Vella S, Andreoni M. Association between cellular human immunodeficiency virus DNA level and immunological parameters in patients with undetectable plasma viremia level during highly active antiretroviral therapy. J Clin Microbiol 2005, 43(12):6183-6185. 10.1128/JCM.43.12.6183-6185.2005, 1317166, 16333125.
16. Izopet J, Salama G, Pasquier C, Sandres K, Marchou B, Massip P, Puel J. Decay of HIV-1 DNA in patients receiving suppressive antiretroviral therapy. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 19(5):478-483. 10.1097/00042560-199812150-00006, 9859961.
17. Ibanez A, Puig T, Elias J, Clotet B, Ruiz L, Martinez MA. Quantification of integrated and total HIV-1 DNA after long-term highly active antiretroviral therapy in HIV-1-infected patients. AIDS 1999, 13(9):1045-1049. 10.1097/00002030-199906180-00007, 10397534.
18. Viard JP, Burgard M, Hubert JB, Aaron L, Rabian C, Pertuiset N, Lourenco M, Rothschild C, Rouzioux C. Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level. AIDS 2004, 18(1):45-49. 10.1097/00002030-200401020-00005, 15090828.
19. Burgard M, Izopet J, Dumon B, Tamalet C, Descamps D, Ruffault A, Vabret A, Bargues G, Mouroux M, Pellegrin I, Ivanoff S, Guisthau O, Calvez V, Seigneurin JM, Rouzioux C. HIV RNA and HIV DNA in peripheral blood mononuclear cells are consistent markers for estimating viral load in patients undergoing long-term potent treatment. AIDS Res Hum Retroviruses 2000, 16(18):1939-1947. 10.1089/088922200750054666, 11153076.
20. Saitoh A, Hsia K, Fenton T, Powell CA, Christopherson C, Fletcher CV, Starr SE, Spector SA. Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children. J Infect Dis 2002, 185(10):1409-1416. 10.1086/340614, 11992275.
21. Furtado MR, Callaway DS, Phair JP, Kunstman KJ, Stanton JL, Macken CA, Perelson AS, Wolinsky SM. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 1999, 340(21):1614-1622. 10.1056/NEJM199905273402102, 10341273.
22. Nicastri E, Palmisano L, Sarmati L, D'Ettorre G, Parisi S, Andreotti M, Buonomini A, Pirillo FM, Narciso P, Bellagamba R, Vullo V, Montano M, Di Perri G, Andreoni M. HIV-1 residual viremia and proviral DNA in patients with suppressed plasma viral load (<400 HIV-RNA cp/ml) during different antiretroviral regimens. Curr HIV Res 2008, 6(3):261-266. 10.2174/157016208784325010, 18473790.
23. Buzon MJ, Massanella M, Llibre JM, Esteve A, Dahl V, Puertas MC, Gatell JM, Domingo P, Paredes R, Sharkey M, Palmer S, Stevenson M, Clotet B, Blanco J, Martinez-Picado J. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 2010, 16(4):460-465. 10.1038/nm.2111, 20228817.
24. Ngo-Giang-Huong N, Deveau C, Da Silva I, Pellegrin I, Venet A, Harzic M, Sinet M, Delfraissy JF, Meyer L, Goujard C, Rouzioux C. Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy. AIDS 2001, 15(6):665-673. 10.1097/00002030-200104130-00001, 11371680.
25. Andreoni M, Parisi SG, Sarmati L, Nicastri E, Ercoli L, Mancino G, Sotgiu G, Mannazzu M, Trevenzoli M, Tridente G, Concia E, Aceti A. Cellular proviral HIV-DNA decline and viral isolation in naive subjects with <5000 copies/ml of HIV-RNA and >500 × 10(6)/l CD4 cells treated with highly active antiretroviral therapy. AIDS 2000, 14(1):23-29. 10.1097/00002030-200001070-00003, 10714564.
26. Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci USA 1998, 95(15):8869-8873. 10.1073/pnas.95.15.8869, 21169, 9671771.
27. Schacker T, Little S, Connick E, Gebhard-Mitchell K, Zhang ZQ, Krieger J, Pryor J, Havlir D, Wong JK, Richman D, Corey L, Haase AT. Rapid accumulation of human immunodeficiency virus (HIV) in lymphatic tissue reservoirs during acute and early HIV infection: implications for timing of antiretroviral therapy. J Infect Dis 2000, 181(1):354-357. 10.1086/315178, 10608788.
28. Pasternak AO, Jurriaans S, Bakker M, Berkhout B, Lukashov VV. Steady increase in cellular HIV-1 load during the asymptomatic phase of untreated infection despite stable plasma viremia. AIDS 2010, 24(11):1641-1649. 10.1097/QAD.0b013e32833b3171, 20543660.
29. Minga AK, Anglaret X, d'Aquin Toni T, Chaix ML, Dohoun L, Abo Y, Coulibaly A, Duvignac J, Gabillard D, Rouet F, Rouzioux C. HIV-1 DNA in peripheral blood mononuclear cells is strongly associated with HIV-1 disease progression in recently infected West African adults. J Acquir Immune Defic Syndr 2008, 48(3):350-354.
30. Rouzioux C, Hubert JB, Burgard M, Deveau C, Goujard C, Bary M, Sereni D, Viard JP, Delfraissy JF, Meyer L. Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+ T cell counts. J Infect Dis 2005, 192(1):46-55. 10.1086/430610, 15942893.
31. Riva E, Pistello M, Narciso P, D'Offizi G, Isola P, Galati V, Turriziani O, Tozzi V, Vincenzi L, Dianzani F, Antonelli G. Decay of HIV type 1 DNA and development of drug-resistant mutants in patients with primary HIV type 1 infection receiving highly active antiretroviral therapy. AIDS Res Hum Retroviruses 2001, 17(17):1599-1604. 10.1089/088922201753342004, 11779347.
32. Zaunders JJ, Cunningham PH, Kelleher AD, Kaufmann GR, Jaramillo AB, Wright R, Smith D, Grey P, Vizzard J, Carr A, Cooper DA. Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia. J Infect Dis 1999, 180(2):320-329. 10.1086/314880, 10395845.
33. Carr JM, Cheney KM, Coolen C, Davis A, Shaw D, Ferguson W, Chang G, Higgins G, Burrell C, Li P. Development of methods for coordinate measurement of total cell-associated and integrated human immunodeficiency virus type 1 (HIV-1) DNA forms in routine clinical samples: levels are not associated with clinical parameters, but low levels of integrated HIV-1 DNA may be prognostic for continued successful therapy. J Clin Microbiol 2007, 45(4):1288-1297. 10.1128/JCM.01926-06, 1865852, 17314225.
34. Rozera G, Abbate I, Bruselles A, Bartolini B, D'Offizi G, Nicastri E, Tommasi C, Capobianchi MR. Comparison of real-time PCR methods for measurement of HIV-1 proviral DNA. J Virol Methods 2010, 164(1-2):135-138. 10.1016/j.jviromet.2009.11.031, 19963009.
35. Torti C, Quiros-Roldan ME, Cologni G, Nichelatti M, Ceresoli F, Pinti M, Nasi M, Cossarizza A, Lapadula G, Costarelli S, Manca N, Gargiulo F, Magoni M, Carosi G. Plasma HIV load and proviral DNA decreases after two standard antiretroviral regimens in HIV-positive patients naive to antiretrovirals. Curr HIV Res 2008, 6(1):43-48. 10.2174/157016208783571982, 18288974.
36. Goicoechea M, Smith DM, Liu L, May S, Tenorio AR, Ignacio CC, Landay A, Haubrich R. Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA. J Infect Dis 2006, 194(1):29-37. 10.1086/504718, 16741879.